{"id":"NCT00262080","sponsor":"Shire","briefTitle":"Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)","officialTitle":"A Double-blind, Placebo-controlled Study (72 Patients, Randomized 1:1) Followed by a Repeat-dosing Phase to Assess the Efficacy and Safety of DX-88 (Ecallantide; Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12-31","primaryCompletion":"2005-12-31","completion":"2007-02-28","firstPosted":"2005-12-06","resultsPosted":"2010-05-11","lastUpdate":"2021-06-11"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema (HAE)"],"interventions":[{"type":"DRUG","name":"ecallantide","otherNames":["DX-88"]},{"type":"DRUG","name":"Phosphate Buffer Saline (PBS),","otherNames":[]}],"arms":[{"label":"DX-88 (ecallantide)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.","primaryOutcome":{"measure":"Treatment Outcome Score at 4 Hours Post-Dose","timeFrame":"4 hours post-dose (DOUBLE-BLIND PART)","effectByArm":[{"arm":"Ecallantide","deltaMin":49.5,"sd":59.43},{"arm":"Placebo","deltaMin":18.5,"sd":67.78}],"pValues":[{"comp":"OG000 vs OG001","p":"0.037"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["24712435","23878046","23548529","22765833","21130380","20818887"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":36},"commonTop":["Headache","Nasopharyngitis","Nausea","Diarrhoea","Hereditary Angioedema"]}}